Role of multimodal imaging in the evaluation of anatomic alterations in neovascular Age-Related Macular Degeneration (AMD) subjects: 18 month Phase 2a open label study of Fovista (anti-PDGF therapy) administered in combination with anti-VEGF therapy

Trial Profile

Role of multimodal imaging in the evaluation of anatomic alterations in neovascular Age-Related Macular Degeneration (AMD) subjects: 18 month Phase 2a open label study of Fovista (anti-PDGF therapy) administered in combination with anti-VEGF therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 16 May 2017

At a glance

  • Drugs Pegpleranib (Primary) ; Aflibercept; Bevacizumab; Ranibizumab
  • Indications Age-related macular degeneration
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors OphthoTech Corporation
  • Most Recent Events

    • 14 May 2017 Status changed from recruiting to completed.
    • 16 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top